ZA200607181B - Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone - Google Patents

Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone Download PDF

Info

Publication number
ZA200607181B
ZA200607181B ZA200607181A ZA200607181A ZA200607181B ZA 200607181 B ZA200607181 B ZA 200607181B ZA 200607181 A ZA200607181 A ZA 200607181A ZA 200607181 A ZA200607181 A ZA 200607181A ZA 200607181 B ZA200607181 B ZA 200607181B
Authority
ZA
South Africa
Prior art keywords
ppm
hydroxycodeinone
composition
oxycodone
oxycodone hydrochloride
Prior art date
Application number
ZA200607181A
Other languages
English (en)
Inventor
Robert Chapman
Lonn S Rider
Qi Hong
Donald Kyle
Robert Kupper
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200607181(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of ZA200607181B publication Critical patent/ZA200607181B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
ZA200607181A 2004-03-30 2006-08-29 Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone ZA200607181B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60153404P 2004-08-13 2004-08-13
US62007204P 2004-10-18 2004-10-18
US64862505P 2005-01-31 2005-01-31
US65177805P 2005-02-10 2005-02-10

Publications (1)

Publication Number Publication Date
ZA200607181B true ZA200607181B (en) 2007-11-28

Family

ID=35124996

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200607181A ZA200607181B (en) 2004-03-30 2006-08-29 Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone

Country Status (39)

Country Link
US (35) US7129248B2 (ja)
EP (7) EP2426132B1 (ja)
JP (8) JP4912294B2 (ja)
KR (12) KR101200700B1 (ja)
CN (5) CN102838607B (ja)
AP (1) AP2232A (ja)
AR (1) AR049012A1 (ja)
AT (2) ATE501150T1 (ja)
AU (2) AU2005230826C1 (ja)
BR (1) BRPI0508758B8 (ja)
CA (3) CA2774121C (ja)
CR (2) CR8593A (ja)
CY (5) CY1111487T1 (ja)
DE (2) DE602005026786D1 (ja)
DK (6) DK2319846T3 (ja)
EA (1) EA013208B1 (ja)
EC (1) ECSP066953A (ja)
ES (6) ES2566363T3 (ja)
FI (1) FI7843U1 (ja)
HK (3) HK1098745A1 (ja)
HR (5) HRP20110425T4 (ja)
HU (3) HUE029913T2 (ja)
IL (8) IL178038A (ja)
LT (2) LT2314589T (ja)
MA (1) MA28492B1 (ja)
ME (4) ME02482B (ja)
MX (2) MX363228B (ja)
MY (3) MY172063A (ja)
NO (1) NO337669B1 (ja)
NZ (3) NZ549430A (ja)
PE (1) PE20050880A1 (ja)
PL (5) PL2316837T3 (ja)
PT (5) PT2426132E (ja)
RS (5) RS53891B1 (ja)
SG (3) SG10201406658VA (ja)
SI (5) SI1730151T2 (ja)
TW (3) TW201509943A (ja)
WO (1) WO2005097801A1 (ja)
ZA (1) ZA200607181B (ja)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
EP1658054B1 (de) * 2003-08-06 2007-06-27 Grünenthal GmbH Gegen missbrauch gesicherte darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
ATE430153T1 (de) * 2005-03-04 2009-05-15 Euro Celtique Sa Verfahren zur verminderung von alpha, beta- ungesättigten ketonen in opioidzusammensetzungen
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
EP2402346A1 (en) 2005-11-22 2012-01-04 Controlled Chemicals, Inc. Processes for reducing contaminating Michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
DE602007003197D1 (de) * 2006-03-02 2009-12-24 Mallinckrodt Inc Verfahren zur herstellung von morphinan-6-on-produkten mit geringen konzentrationen von alpha-, beta-ungesättigten ketonverbindungen
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
AU2007313103C1 (en) * 2006-10-17 2014-01-30 Penick Corporation Process for preparing oxymorphone
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
JP2010511726A (ja) 2006-12-04 2010-04-15 ノランコ・インコーポレーテツド １４−ヒドロキシコデイノンの濃度が低いオキシコドンの製造方法
JP2010511725A (ja) * 2006-12-04 2010-04-15 ノランコ・インコーポレーテツド オキシコドン塩基中の不純物を減少させる方法
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8217175B2 (en) * 2007-03-23 2012-07-10 Mallinckrodt Llc Preparation of oxymorphone from oripavine
US8309727B2 (en) * 2007-04-16 2012-11-13 Mallinckrodt Llc Opiate reduction utilizing catalytic hydrogen transfer reaction
CN102014877B (zh) 2008-01-25 2017-06-06 格吕伦塔尔有限公司 药物剂型
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
JP5607550B2 (ja) * 2008-03-11 2014-10-15 ディポメド，インコーポレイティド 非オピオイド鎮痛剤及びオピオイド鎮痛剤の組合せを含む胃保持性持続放出剤形
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
ES2586439T3 (es) * 2008-09-18 2016-10-14 Purdue Pharma Lp Formas farmacéuticas de dosificación que comprenden poli (E-caprolactona)
NZ596667A (en) * 2009-07-22 2013-09-27 Gruenenthal Chemie Hot-melt extruded controlled release dosage form
TWI473628B (zh) * 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
WO2011026125A2 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
EP2488029B1 (en) 2009-09-30 2016-03-23 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
ES2606227T3 (es) * 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
MX344846B (es) 2010-05-10 2017-01-10 Euro-Celtique S A * Combinacion de granulos cargados activos con activos adicionales.
TWI483748B (zh) 2010-05-10 2015-05-11 Euro Celtique Sa 含有氫嗎啡酮（ｈｙｄｒｏｍｏｒｐｈｏｎｅ）和納洛酮（ｎａｌｏｘｏｎｅ）之藥學組成物
WO2011154826A1 (en) 2010-06-11 2011-12-15 Rhodes Technologies Process for n-dealkylation of tertiary amines
EP2580201B1 (en) 2010-06-11 2017-08-02 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
US8703950B2 (en) 2010-07-02 2014-04-22 Johnson Matthey Public Limited Co. Low ABUK oxycodone, its salts and methods of making same
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
CN103269688A (zh) 2010-09-02 2013-08-28 格吕伦塔尔有限公司 包含无机盐的抗破碎剂型
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
NO2736497T3 (ja) 2011-07-29 2018-01-20
NO2736495T3 (ja) 2011-07-29 2018-01-20
EP2748000B1 (en) 2011-09-05 2020-11-18 Siegfried Ltd. Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
US20140294947A1 (en) 2011-09-16 2014-10-02 Purdue Pharma L.P. Tamper resistant immediate release formulations
MX355478B (es) 2011-09-16 2018-04-19 Purdue Pharma Lp Formulaciones farmacéuticas resistentes a la manipulación.
CN107854434A (zh) 2011-12-09 2018-03-30 普渡制药公司 包含聚(ε‑己内酯)和聚氧乙烯的药物剂型
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
CA2852042C (en) 2012-03-02 2018-05-01 Rhodes Pharmaceuticals L.P. Tamper resistant immediate release formulations
CA2868413C (en) 2012-04-17 2021-07-20 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
RS57913B1 (sr) 2012-04-18 2019-01-31 Gruenenthal Gmbh Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6031599B2 (ja) 2012-07-12 2016-11-24 マリンクロッド エルエルシー 長期放出性、濫用抑止特性薬学的組成物
TWI643859B (zh) * 2012-07-16 2018-12-11 羅德科技公司 改良之類鴉片合成方法
UA117226C2 (uk) * 2012-07-16 2018-07-10 Родес Текнолоджіс Спосіб покращеного синтезу опіоїду
RU2639877C2 (ru) * 2012-08-03 2017-12-25 Джонсон Мэтти Паблик Лимитед Компани Способ получения оксикодона
CN107595793B (zh) 2012-11-30 2020-11-13 阿库拉制药公司 活性药物成分的自调节释放
SG11201506064UA (en) 2013-02-05 2015-08-28 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
US9770710B2 (en) 2013-02-20 2017-09-26 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
BR112015029616A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem resistente à adulteração com perfil de liberação bimodal
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
EP3019157A1 (en) 2013-07-12 2016-05-18 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
AU2014298257B2 (en) 2013-08-02 2016-11-10 Macfarlan Smith Limited Process for the preparation of oxymorphone
PL3065743T3 (pl) 2013-11-07 2019-12-31 SpecGx LLC Sposób wytwarzania 6-hydroksymorfinanów bez izolowania związków pośrednich
NZ719087A (en) 2013-11-13 2017-12-22 Euro Celtique Sa Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
AU2015207734B2 (en) 2014-01-15 2017-02-23 Rhodes Technologies Process for improved oxymorphone synthesis
AU2015207733A1 (en) 2014-01-15 2016-07-14 Rhodes Technologies Process for improved oxycodone synthesis
WO2015120201A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma, Llc Abuse-resistant drug formulations with built-in overdose protection
EP3122337A4 (en) 2014-03-26 2017-11-08 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release coated reservoir solid dosage form
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
US20170342084A1 (en) 2014-07-09 2017-11-30 Rhodes Technologies Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
US20160310429A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2018055199A1 (en) 2016-09-26 2018-03-29 Euro-Celtique S.A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2018234748A1 (en) 2017-06-20 2018-12-27 Johnson Matthey Public Limited Company HYDROGENATION PROCESS FOR THE PREPARATION OF OXYCODONE HYDROCHLORIDE FROM 14-HYDROXYCODEINONE
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
US1485673A (en) * 1924-03-04 Ministrator
US1468805A (en) 1923-09-25 Htabtin ereund
DE296916C (ja) *
DE286431C (ja)
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
US420098A (en) * 1890-01-28 Mowing-machine
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (ja) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (ja) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4272540A (en) 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) * 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4639520A (en) 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
KR930001499B1 (ko) * 1987-07-07 1993-03-02 오끼뎅끼 고오교오 가부시끼가이샤 반도체 장치의 제조방법
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
DE09003265T1 (de) 1996-06-26 2010-04-29 Board of Regents, The University of Texas System, Austin Extrudierbare pharmazeutische Schmelzklebstoffformulierung
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) * 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
ATE251017T1 (de) * 1998-10-14 2003-10-15 Gyros Ab Form und verfahren zu deren herstellung
US6177567B1 (en) * 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
AP1665A (en) * 2000-02-08 2006-09-22 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
US20030194748A1 (en) 2000-05-29 2003-10-16 Tohru Nagasaki Method for labeling with tritium
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
TWI255186B (en) * 2001-06-05 2006-05-21 Control Delivery Sys Inc Sustained-release analgesic compounds
WO2002100382A2 (en) 2001-06-08 2002-12-19 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
JP4669224B2 (ja) * 2002-01-15 2011-04-13 エアロジェン，インコーポレイテッド 有効解剖学的死腔からのエアロゾルを浄化するためのシステムおよび方法
DK1578350T3 (da) * 2002-03-26 2009-08-10 Euro Celtique Sa Sammensætninger med gel-coating med depotvirkning
NZ536252A (en) * 2002-04-29 2007-06-29 Alza Corp Methods and dosage forms for controlled delivery of oxycodone
EP1509050A4 (en) * 2002-05-27 2009-03-18 Ntt Docomo Inc MOBILE COMMUNICATION SYSTEM, TRANSMISSION STATION, RECEPTION STATION, RELAY STATION, COMMUNICATION PATH DECISION METHOD, AND COMMUNICATION PATH DECISION SOFTWARE
AU2003245345A1 (en) 2002-05-31 2003-12-19 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
CA2491572C (en) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
EP1537118A1 (en) * 2002-08-15 2005-06-08 Noramco, Inc. Oxycodone-hydrochloride polymorhs
US7192966B2 (en) 2002-11-15 2007-03-20 Branded Products For The Future Pharmaceutical composition
MXPA05005781A (es) * 2002-11-29 2005-12-12 Forest Laboratories Combinacion de ibuprofeno y oxicodona para alivio de dolor agudo.
FR2850576B1 (fr) 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
WO2004082620A2 (en) 2003-03-13 2004-09-30 Controlled Chemicals, Inc. Oxycodone conjugates with lower the abuse potential and extended duration of action
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
WO2005098414A1 (en) * 2004-03-30 2005-10-20 Euro-Celtique S.A Methods for detecting 14-hydroxycodeinone and codeinone
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
WO2006004672A1 (en) 2004-06-25 2006-01-12 Tessera, Inc. Components with posts and pads
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
ATE430153T1 (de) 2005-03-04 2009-05-15 Euro Celtique Sa Verfahren zur verminderung von alpha, beta- ungesättigten ketonen in opioidzusammensetzungen
EP1893616B1 (en) 2005-06-16 2010-12-29 Mallinckrodt, Inc. A synthetic route to 14-hydroxyl opiates through 1-halo-thebaine or analogs
EP2402346A1 (en) 2005-11-22 2012-01-04 Controlled Chemicals, Inc. Processes for reducing contaminating Michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
DE602007003197D1 (de) 2006-03-02 2009-12-24 Mallinckrodt Inc Verfahren zur herstellung von morphinan-6-on-produkten mit geringen konzentrationen von alpha-, beta-ungesättigten ketonverbindungen
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
JP2010511726A (ja) * 2006-12-04 2010-04-15 ノランコ・インコーポレーテツド １４−ヒドロキシコデイノンの濃度が低いオキシコドンの製造方法
JP2010511725A (ja) 2006-12-04 2010-04-15 ノランコ・インコーポレーテツド オキシコドン塩基中の不純物を減少させる方法
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
US8703950B2 (en) * 2010-07-02 2014-04-22 Johnson Matthey Public Limited Co. Low ABUK oxycodone, its salts and methods of making same
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Also Published As

Publication number Publication date
DK1730151T3 (da) 2011-06-20
RS54941B1 (sr) 2016-11-30
HK1155728A1 (en) 2012-05-25
JP2018184462A (ja) 2018-11-22
RS51693B2 (sr) 2021-02-26
US9073933B2 (en) 2015-07-07
US20160185790A1 (en) 2016-06-30
PT1730151E (pt) 2011-06-01
US20070117829A1 (en) 2007-05-24
EP2316837B1 (en) 2018-01-10
US20190161492A1 (en) 2019-05-30
US20160176888A1 (en) 2016-06-23
ECSP066953A (es) 2006-12-20
SI1730151T2 (sl) 2021-03-31
US20160185789A1 (en) 2016-06-30
SI2305683T1 (sl) 2015-04-30
JP2012072162A (ja) 2012-04-12
HRP20110425T1 (en) 2011-07-31
PT2305683E (pt) 2015-05-18
JP2011157370A (ja) 2011-08-18
CA2774121C (en) 2016-02-16
IL241117A0 (en) 2015-11-30
CN1960994A (zh) 2007-05-09
US20200062772A1 (en) 2020-02-27
IL213890A (en) 2015-10-29
BRPI0508758B8 (pt) 2021-05-25
KR20100069719A (ko) 2010-06-24
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
EP1730151A1 (en) 2006-12-13
EA013208B1 (ru) 2010-04-30
RS54598B1 (en) 2016-08-31
PT2319846T (pt) 2016-08-12
KR101200700B1 (ko) 2012-11-13
DE602005026786D1 (de) 2011-04-21
NZ549430A (en) 2010-05-28
DK200700214U1 (da) 2007-11-23
EP2319846B1 (en) 2016-05-04
IL178038A0 (en) 2006-12-31
EP2314589B1 (en) 2022-12-28
HK1098745A1 (en) 2007-07-27
BRPI0508758B1 (pt) 2018-10-09
KR20140021716A (ko) 2014-02-20
CA2774121A1 (en) 2005-10-20
CA2913355C (en) 2021-04-20
EP2305683B8 (en) 2015-03-04
MY172063A (en) 2019-11-13
JP5118223B2 (ja) 2013-01-16
KR20130020962A (ko) 2013-03-04
EP1730151B2 (en) 2020-09-16
US10259819B2 (en) 2019-04-16
CN102127086A (zh) 2011-07-20
SI2319846T1 (sl) 2016-08-31
CA2913355A1 (en) 2005-10-20
CN102838607A (zh) 2012-12-26
US20200087316A1 (en) 2020-03-19
DK2316837T3 (en) 2018-04-16
TW201231469A (en) 2012-08-01
MX2020008878A (es) 2020-11-09
PL2316837T3 (pl) 2018-07-31
FIU20070284U0 (fi) 2007-07-04
PE20050880A1 (es) 2005-11-16
IL214050A0 (en) 2011-08-31
KR20090104145A (ko) 2009-10-05
SI2426132T1 (sl) 2016-04-29
ME02482B (me) 2017-02-20
MA28492B1 (fr) 2007-03-01
EP2316837A1 (en) 2011-05-04
CR20110376A (es) 2011-09-19
AR049012A1 (es) 2006-06-21
CY1117841T1 (el) 2017-05-17
AT9952U1 (de) 2008-06-15
MY143205A (en) 2011-03-31
US20160185788A1 (en) 2016-06-30
HRP20180407T1 (hr) 2018-04-20
JP6503392B2 (ja) 2019-04-17
AU2009200335B2 (en) 2011-07-28
US20160175299A1 (en) 2016-06-23
DK2426132T3 (en) 2016-04-04
ATE501150T1 (de) 2011-03-15
CA2557845C (en) 2013-10-01
PT2426132E (pt) 2016-03-31
CY1120171T1 (el) 2018-12-12
CN102887903A (zh) 2013-01-23
FI7843U1 (fi) 2008-04-28
US20160251365A1 (en) 2016-09-01
US12060361B2 (en) 2024-08-13
DK1730151T4 (da) 2020-10-19
US7674799B2 (en) 2010-03-09
JP2007531756A (ja) 2007-11-08
US20160176889A1 (en) 2016-06-23
JP5543991B2 (ja) 2014-07-09
US11384091B2 (en) 2022-07-12
US20130005977A1 (en) 2013-01-03
SG170735A1 (en) 2011-05-30
CY1116327T1 (el) 2017-02-08
DK200700214U3 (da) 2008-02-08
US9522919B2 (en) 2016-12-20
LT2316837T (lt) 2018-04-10
CN101812065A (zh) 2010-08-25
AP2006003738A0 (en) 2006-10-31
NO20064935L (no) 2006-12-18
ME03068B (me) 2019-01-20
IL214050A (en) 2013-09-30
IL213890A0 (en) 2011-07-31
EP2314589A1 (en) 2011-04-27
US10407434B2 (en) 2019-09-10
CR8593A (es) 2007-07-19
EP2426132A1 (en) 2012-03-07
US9777011B2 (en) 2017-10-03
US20090227615A1 (en) 2009-09-10
AU2005230826A1 (en) 2005-10-20
PL1730151T3 (pl) 2011-08-31
KR20110110377A (ko) 2011-10-06
NO337669B1 (no) 2016-05-30
PL2426132T3 (pl) 2016-06-30
ES2585576T3 (es) 2016-10-06
SG10201406658VA (en) 2014-12-30
PL2305683T3 (pl) 2015-07-31
US7683072B2 (en) 2010-03-23
KR101410141B1 (ko) 2014-06-25
US20070179169A1 (en) 2007-08-02
US10689389B2 (en) 2020-06-23
JP2012188439A (ja) 2012-10-04
NZ601326A (en) 2013-10-25
ME02411B (me) 2016-09-20
TW201509943A (zh) 2015-03-16
US20160250204A1 (en) 2016-09-01
SI1730151T1 (sl) 2011-06-30
US20050222188A1 (en) 2005-10-06
US7674798B2 (en) 2010-03-09
US20160175298A1 (en) 2016-06-23
US10696684B2 (en) 2020-06-30
KR20070022033A (ko) 2007-02-23
ES2938727T3 (es) 2023-04-14
CY1111487T1 (el) 2015-08-05
US20160251363A1 (en) 2016-09-01
TWI365880B (en) 2012-06-11
HRP20160223T1 (hr) 2016-03-25
US20160251364A1 (en) 2016-09-01
DK2319846T3 (en) 2016-08-15
IL213891A0 (en) 2011-07-31
US7674800B2 (en) 2010-03-09
IL178038A (en) 2015-10-29
IL235298A (en) 2016-11-30
EP2319846A1 (en) 2011-05-11
ES2566363T3 (es) 2016-04-12
HRP20150358T1 (hr) 2015-05-08
ES2362282T5 (es) 2021-06-24
KR20120046309A (ko) 2012-05-09
KR20150046393A (ko) 2015-04-29
US20070117830A1 (en) 2007-05-24
TW200540177A (en) 2005-12-16
US20160250205A1 (en) 2016-09-01
IL213888A0 (en) 2011-07-31
CY1117228T1 (el) 2017-04-05
BRPI0508758A (pt) 2007-08-28
AU2005230826B2 (en) 2008-11-06
PL1730151T5 (pl) 2023-09-18
US20150265598A1 (en) 2015-09-24
JP4912294B2 (ja) 2012-04-11
RS51693B (en) 2011-10-31
CN102887903B (zh) 2016-01-27
HRP20160885T1 (hr) 2016-09-23
AU2005230826C1 (en) 2014-10-16
CN101812065B (zh) 2012-03-28
CA2557845A1 (en) 2005-10-20
PT2316837T (pt) 2018-04-02
IL241117B (en) 2020-06-30
AP2232A (en) 2011-05-04
MY154985A (en) 2015-08-28
LT2314589T (lt) 2023-06-12
US20230365578A1 (en) 2023-11-16
CN102838607B (zh) 2016-08-03
IL213889A (en) 2012-06-28
ES2535618T3 (es) 2015-05-13
US20160264588A1 (en) 2016-09-15
RS57000B1 (sr) 2018-05-31
ES2665287T3 (es) 2018-04-25
US20100152449A1 (en) 2010-06-17
DK2305683T3 (en) 2015-04-07
TWI483944B (zh) 2015-05-11
RS53891B1 (en) 2015-08-31
EP2305683A1 (en) 2011-04-06
HUE029913T2 (en) 2017-04-28
US20150258086A1 (en) 2015-09-17
US20060173029A1 (en) 2006-08-03
ES2362282T3 (es) 2011-06-30
KR100993911B1 (ko) 2010-11-11
US20110207762A1 (en) 2011-08-25
US20210198268A1 (en) 2021-07-01
HUE028233T2 (en) 2016-12-28
US20150265597A1 (en) 2015-09-24
KR100930730B1 (ko) 2009-12-09
US20160175300A1 (en) 2016-06-23
US20180022754A1 (en) 2018-01-25
US20070117831A1 (en) 2007-05-24
SI2316837T1 (en) 2018-05-31
EP1730151B1 (en) 2011-03-09
ME01299B (me) 2011-10-31
CN102127086B (zh) 2013-11-27
HK1155729A1 (zh) 2012-05-25
HRP20110425T4 (hr) 2020-11-27
JP2015187134A (ja) 2015-10-29
HUE036451T2 (hu) 2018-07-30
US8822687B2 (en) 2014-09-02
IL213889A0 (en) 2011-07-31
KR20140133615A (ko) 2014-11-19
DE202005021371U1 (de) 2007-10-25
JP2014139205A (ja) 2014-07-31
JP2017125052A (ja) 2017-07-20
MX363228B (es) 2019-03-15
US20210094963A1 (en) 2021-04-01
PL2319846T3 (pl) 2016-12-30
EP2305683B1 (en) 2015-01-28
US20230159548A1 (en) 2023-05-25
KR20120106784A (ko) 2012-09-26
CN1960994B (zh) 2012-09-05
EA200601520A1 (ru) 2007-02-27
EP2426132B1 (en) 2016-01-13
KR20180088505A (ko) 2018-08-03
SG170736A1 (en) 2011-05-30
JP5378486B2 (ja) 2013-12-25
EP1730151A4 (en) 2007-05-23
KR20200000499A (ko) 2020-01-02
US7129248B2 (en) 2006-10-31
EP2311839A1 (en) 2011-04-20
WO2005097801A1 (en) 2005-10-20
AU2009200335A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
US12060361B2 (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
AU2011213801B2 (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
AU2015261590A1 (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone